These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 6571182

  • 21. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
    Lingnau A, Miller K, Steiner U, Jentzmik F, Weikert S, Schostak M.
    Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135
    [Abstract] [Full Text] [Related]

  • 22. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS, Chow NH, Lin JS, Yang WH, Tong YC.
    Anticancer Res; 1998 Sep; 18(6B):4717-21. PubMed ID: 9891547
    [Abstract] [Full Text] [Related]

  • 23. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
    Besarani D, Al-Akraa M.
    BJU Int; 2006 Jul; 98(1):232-3. PubMed ID: 16831177
    [No Abstract] [Full Text] [Related]

  • 24. Superficial bladder cancer--treatment approach.
    Abi-Aad A, Biquet P, Penders L.
    Acta Urol Belg; 1996 May; 64(2):19-24. PubMed ID: 8701801
    [No Abstract] [Full Text] [Related]

  • 25. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT, Soloway MS.
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Risk-adapted use of intravesical chemotherapy.
    Lerner SP, Au JL.
    BJU Int; 2008 Nov; 102(9 Pt B):1247-53. PubMed ID: 19035889
    [No Abstract] [Full Text] [Related]

  • 29. [Can the persistence rate of transurethrally resected bladder tumors be lowered by postoperative instillation of silver nitrate?].
    Flamm J, Grof F.
    Z Urol Nephrol; 1984 Jan; 77(1):1-6. PubMed ID: 6702326
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ, Shen ZJ, Lu J, Jin XD, Chen J, Shi SF.
    Zhonghua Wai Ke Za Zhi; 2005 Nov 15; 43(22):1457-60. PubMed ID: 16318813
    [Abstract] [Full Text] [Related]

  • 34. [Transurethral resection in large non-invasive tumors of the bladder].
    Sánchez de Badajoz E.
    Arch Esp Urol; 1985 Nov 15; 38(4):393-400. PubMed ID: 4073965
    [No Abstract] [Full Text] [Related]

  • 35. Risk-adapted use of intravesical immunotherapy.
    Braasch MR, Böhle A, O'Donnell MA.
    BJU Int; 2008 Nov 15; 102(9 Pt B):1254-64. PubMed ID: 19035890
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Intravesical chemotherapy for superficial bladder tumors category Ta/T1: who should be treated and how?
    Kurth KH.
    Semin Urol Oncol; 1996 Feb 15; 14(1 Suppl 1):30-5. PubMed ID: 8727808
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.